[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR100268A1 - Formulación líquida que comprende compuesto neutralizante de gm-csf - Google Patents

Formulación líquida que comprende compuesto neutralizante de gm-csf

Info

Publication number
AR100268A1
AR100268A1 ARP150101336A ARP150101336A AR100268A1 AR 100268 A1 AR100268 A1 AR 100268A1 AR P150101336 A ARP150101336 A AR P150101336A AR P150101336 A ARP150101336 A AR P150101336A AR 100268 A1 AR100268 A1 AR 100268A1
Authority
AR
Argentina
Prior art keywords
composition according
csf
neutralizing compound
neutralizes
formulation
Prior art date
Application number
ARP150101336A
Other languages
English (en)
Inventor
M Nguyen Phuong
R Dluzio Willow
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of AR100268A1 publication Critical patent/AR100268A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulaciones acuosas que comprenden un compuesto neutralizante que neutraliza GM-CSF en las concentraciones de por lo menos alrededor de 20 mg/ml, un modificador de tonicidad, un buffer y uno o más de agentes tensioactivos, los aminoácidos, antioxidantes y/o queladores, en donde la composición es estable. Los ingredientes de la formulación preferentemente proporcionan estabilidad al compuesto que neutraliza GM-CSF en vista del almacenamiento prolongado. En un aspecto preferido, la formulación es para usar en tratamiento, preferentemente para usar en el tratamiento de trastornos inflamatorios y autoinmunes, preferentemente incluyendo trastornos alérgicos y psoriáticos, además de alteraciones artríticas y asmáticas. Además, se proporciona un kit que comprende la formulación. Reivindicación 4: La composición de acuerdo con la reivindicación 1 hasta 3, en donde el modificador de tonicidad se selecciona de manitol, sorbitol, sacarosa y/o trehalosa. Reivindicación 5: La composición de acuerdo con cualquiera de las reivindicaciones 1 hasta 4, en donde el buffer se selecciona de un buffer de histidina, acetato y/o de citrato. Reivindicación 6: La composición de acuerdo con cualquiera de los puntos 1 hasta 5, en donde el agente tensioactivo se selecciona de uno o más de polisorbato 20, polisorbato 80, poloxámeros y combinaciones de los anteriores. Reivindicación 15: La composición de acuerdo con cualquiera de las reivindicaciones 1 hasta 14, en donde el compuesto que neutraliza GM-CSF se selecciona del grupo que consiste en un polipéptido, un péptido mimético, un ácido nucleico, y una molécula pequeña. Reivindicación 16: La composición de acuerdo con la reivindicación 15, en donde el polipéptido es un anticuerpo o uno de sus fragmentos funcionales que se une a un GM-CSF o al receptor de GM-CSF. Reivindicación 17: La composición de acuerdo con la reivindicación 16, en donde el anticuerpo o el fragmento funcional del mismo es un anticuerpo monoclonal humano o uno de sus fragmentos funcionales. Reivindicación 18: La composición de acuerdo con cualquiera de las reivindicaciones que anteceden que comprende i) alrededor de 50 mg/ml hasta alrededor de 180 mg/ml de un compuesto neutralizante que neutraliza GM-CSF, ii) alrededor de 5% (p/v) de sorbitol, iii) alrededor de 30 mM de L-histidina y iv) desde alrededor de 0,001% hasta alrededor de 1% (p/v) de agente tensioactivo y v) tiene un pH de alrededor de 5,8.
ARP150101336A 2014-05-07 2015-05-04 Formulación líquida que comprende compuesto neutralizante de gm-csf AR100268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14167405 2014-05-07

Publications (1)

Publication Number Publication Date
AR100268A1 true AR100268A1 (es) 2016-09-21

Family

ID=50721582

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101336A AR100268A1 (es) 2014-05-07 2015-05-04 Formulación líquida que comprende compuesto neutralizante de gm-csf

Country Status (15)

Country Link
US (1) US11173208B2 (es)
EP (1) EP3139960B1 (es)
JP (1) JP6769879B2 (es)
KR (1) KR102385802B1 (es)
CN (1) CN106659785B (es)
AR (1) AR100268A1 (es)
AU (1) AU2015257798C1 (es)
BR (1) BR112016025126B1 (es)
CA (1) CA2946230A1 (es)
EA (1) EA201691883A1 (es)
ES (1) ES2974895T3 (es)
MX (1) MX2016014411A (es)
PH (1) PH12016502100A1 (es)
TW (1) TWI682788B (es)
WO (1) WO2015169742A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
CN107167613B (zh) * 2017-06-22 2018-10-02 深圳清华大学研究院 用于等离子体金芯片的蛋白点样缓冲液
US20240336685A1 (en) * 2018-10-01 2024-10-10 Amgen Inc. Methods for reducing aggregation of bispecific antibodies
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
KR20220099585A (ko) * 2019-10-25 2022-07-13 암젠 인크 낮은 단백질 농도에서 단백질 손실을 최소화하기 위한 조성물 및 방법
WO2022115914A1 (en) * 2020-12-04 2022-06-09 Csl Innovation Methods for treating inflammatory skin conditions
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CN117615788A (zh) * 2021-05-12 2024-02-27 安奈普泰斯生物有限公司 抗体组合物
WO2024114735A1 (en) * 2022-12-01 2024-06-06 I-Mab Biopharma (Hangzhou) Co., Ltd. Liquid pharmaceutical formulation of anti-gm-csf antibody and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3583880D1 (de) 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Cd19×cd3 특이 폴리펩티드 및 그의 용도
DK1441589T3 (da) * 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
ES2618832T3 (es) 2002-02-27 2017-06-22 Immunex Corporation Composición TNFR-FC estabilizada que comprende arginina
US7511476B2 (en) * 2005-01-04 2009-03-31 Digisensors, Inc. Electromagnetic sensor systems and methods of use thereof
EA013162B1 (ru) * 2005-04-18 2010-02-26 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
JP5295759B2 (ja) 2005-05-18 2013-09-18 モルフォシス・アクチェンゲゼルシャフト 抗gm−csf抗体とその使用
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2641169C (en) 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
SI1999152T1 (sl) 2006-03-27 2013-02-28 Medimmune Limited Vezni äślen za gm-csf receptor
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009064399A1 (en) 2007-11-13 2009-05-22 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2009134805A2 (en) 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
CA2738243C (en) * 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
AU2013320261A1 (en) * 2012-09-20 2015-04-09 Morphosys Ag Treatment for rheumatoid arthritis
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf

Also Published As

Publication number Publication date
US20170252436A1 (en) 2017-09-07
AU2015257798C1 (en) 2020-10-22
PH12016502100A1 (en) 2017-02-06
BR112016025126A2 (pt) 2018-02-20
EP3139960B1 (en) 2024-01-17
KR102385802B1 (ko) 2022-04-13
TW201622702A (zh) 2016-07-01
EP3139960A1 (en) 2017-03-15
KR20160149210A (ko) 2016-12-27
JP6769879B2 (ja) 2020-10-14
WO2015169742A1 (en) 2015-11-12
CN106659785A (zh) 2017-05-10
TWI682788B (zh) 2020-01-21
JP2017514868A (ja) 2017-06-08
ES2974895T3 (es) 2024-07-02
US11173208B2 (en) 2021-11-16
EA201691883A1 (ru) 2017-05-31
AU2015257798A1 (en) 2016-11-17
MX2016014411A (es) 2017-04-06
AU2015257798B2 (en) 2020-04-23
BR112016025126A8 (pt) 2022-08-09
BR112016025126B1 (pt) 2024-02-15
CN106659785B (zh) 2021-04-30
CA2946230A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
AR100268A1 (es) Formulación líquida que comprende compuesto neutralizante de gm-csf
AR107014A1 (es) Formulación farmacéutica acuosa
AR093297A1 (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
PE20170780A1 (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
EP4233892A3 (en) Stable anti-ifnar1 formulation
CL2018003178A1 (es) Composición farmacéutica
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
PE20190448A1 (es) Formulacion farmaceutica liquida estable
AR092470A1 (es) Formulaciones acuosas estables de adalimumab
AR112480A1 (es) Composiciones de glp-1 y sus usos
AR050353A1 (es) Composicion de anticuerpo her2
JP2017222654A5 (es)
PE20080121A1 (es) Metodos para reducir la aglomeracion de proteina
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
AR075908A1 (es) Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo.
AR103544A1 (es) FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
AR108631A1 (es) Formulación de neurotoxinas
JP2017514868A5 (es)
AR107708A1 (es) Formulaciones de antagonista de il-6 y sus usos
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf

Legal Events

Date Code Title Description
FC Refusal